The sodium-glucose cotransporter-2 inhibitor (SGLT2i) class of pharmaceuticals dramatically improves important clinical outcomes in patients with type 2 diabetes (T2D) (1) and cardiovascular disease (2, 3) by uncertain mechanisms (4, 5). Here, SLC5A2 is linked to type 2 diabetes mellitus.